Get the Stockscreener App
18.81
0.11%
-0.02
After Hours:
18.85
0.04
+0.21%
Jasper Therapeutics Inc stock is traded at $18.81, with a volume of 121.34K.
It is down -0.11% in the last 24 hours and down -13.72% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$18.83
Open:
$18.72
24h Volume:
121.34K
Relative Volume:
0.56
Market Cap:
$286.55M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-19.00
EPS:
-0.99
Net Cash Flow:
$-52.33M
1W Performance:
-12.65%
1M Performance:
-13.72%
6M Performance:
-35.93%
1Y Performance:
+168.71%
1-Day Range:
$18.56
$19.35
1-Week Range:
$17.37
$23.32
52-Week Range:
$4.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com
Fanconi Anemia Market Expected to Experience Major Growth - openPR
Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics - The Globe and Mail
Jasper Therapeutics (NASDAQ:JSPR) Earns "Market Outperform" Rating from JMP Securities - MarketBeat
Jasper Therapeutics Inc [JSPR] Shares Jump Approximately 156.76% Over the Year - Knox Daily
Insider Selling: Kabot Brian, Momentus Inc [MNTS] Director divested 400 shares - Knox Daily
Jasper Therapeutics Inc (JSPR) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Jasper Therapeutics Inc’s Market Journey: Closing Weak at 18.23, Down -16.34 - The Dwinnex
Jasper concerns driven by Celldex data ‘overdone,’ says Stifel - TipRanks
Front Street Capital Management Inc. Sells 4,073 Shares of Kimball Electronics, Inc. (NASDAQ:KE) - Defense World
First Light Asset Management LLC Sells 482 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - Defense World
Booz Allen Hamilton Holding Co. (NYSE:BAH) Shares Acquired by Providence Capital Advisors LLC - Defense World
Needham maintains Buy rating on Jamf shares with no price target change - Investing.com India
When (JSPR) Moves Investors should Listen - Stock Traders Daily
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLC - Defense World
Jasper is open to visitors again — but what can tourists expect? - CBC.ca
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Massachusetts Financial Services Co. MA Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Ally Bridge Group NY LLC Trims Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Quest Partners LLC Has $40,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
"Let’s go crazy in front of the best fans": Kentucky's Jasper Johnson tries to lure Caleb Wilson and Acaden Lewis to the Wildcats - Sportskeeda
Jasper Johnson pitches Kentucky to Caleb Wilson and Acaden Lewis - KSR
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Increases By 8.7% - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Large Increase in Short Interest - MarketBeat
Sources Say goes LIVE with Kentucky commit Jasper Johnson! - KSR
Aquestive Therapeutics Inc’s latest rating changes from various analysts - Knox Daily
Jewett-Cameron Adds Three New Supply Partners for its Products - NRToday.com
Jasper Johnson had a month of being "torn" before committing to Kentucky - A Sea Of Blue
Jasper lifting state of local emergency, receives 13 EOIs for interim housing - Hamilton Spectator
Quest Partners LLC Purchases 982 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) - Defense World
Financial Analysis: ADMA Biologics (NASDAQ:ADMA) vs. Jasper Therapeutics (NASDAQ:JSPR) - Defense World
Jasper state of local emergency ending; visitors asked to be respectful - CTV News Edmonton
Jasper ending state of emergency as focus shifts to long-term recovery from wildfire - Winnipeg Free Press
Jasper Therapeutics COO sells shares worth over $19,000 By Investing.com - Investing.com Australia
(JSPR) Trading Report - Stock Traders Daily
Jasper Therapeutics COO sells shares worth over $19,000 - Investing.com
Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells $19,107.00 in Stock - MarketBeat
Jasper Therapeutics gets Canada nod for asthma study - Investing.com
Jasper Therapeutics Announces Health Canada Clearance of - GlobeNewswire
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma - StockTitan
Jasper Therapeutics (NASDAQ:JSPR) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at JMP Securities - Defense World
Cantor Fitzgerald Reaffirms "Overweight" Rating for Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics stock set for growth with novel stem cell therapyJMP - Investing.com Canada
JMP Securities Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics initiated with an Outperform at JMP Securities - TipRanks
Addiction Therapeutics Market Current Impact to Make Big Changes - La Funcion mx
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - GlobeNewswire
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - Yahoo Finance UK
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - Yahoo Finance
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):